Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine

Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice

(2017) Christopher R. Chapple et al.   EUROPEAN UROLOGY

Long-term Persistence with Mirabegron versus Solifenacin in Women with Overactive Bladder: Prospective, Randomized Trial

(2016) Manami KINJO et al.   LUTS-Lower Urinary Tract Symptoms

American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults

(2015)   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder

(2014) Osamu Yamaguchi et al.   BJU INTERNATIONAL

Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia

(2014) Hann-Chorng Kuo et al.   NEUROUROLOGY AND URODYNAMICS

The Role of Mirabegron in Overactive Bladder: A Systematic Review and Meta-Analysis

(2014) Tao Wu et al.   UROLOGIA INTERNATIONALIS

Systematic Review of Combination Drug Therapy for Non-neurogenic Male Lower Urinary Tract Symptoms

(2013) Claudius Füllhase et al.   EUROPEAN UROLOGY

Global Prevalence and Economic Burden of Urgency Urinary Incontinence: A Systematic Review

(2013) Ian Milsom et al.   EUROPEAN UROLOGY

Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies

(2013) V. W. Nitti et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

A phase II dose-ranging study of mirabegron in patients with overactive bladder

(2013) Christopher R. Chapple et al.   INTERNATIONAL UROGYNECOLOGY JOURNAL

The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials

(2013) Yuanshan Cui et al.   INTERNATIONAL UROLOGY AND NEPHROLOGY

Urodynamics and Safety of the β3-Adrenoceptor Agonist Mirabegron in Males with Lower Urinary Tract Symptoms and Bladder Outlet Obstruction

(2013) Victor W. Nitti et al.   JOURNAL OF UROLOGY

Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability

(2013) Christopher R. Chapple et al.   NEUROUROLOGY AND URODYNAMICS

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder

(2013) Sender Herschorn et al.   UROLOGY

Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience

(2012) Adrian Wagg et al.   BJU INTERNATIONAL

Proarrhythmic Safety of Repeat Doses of Mirabegron in Healthy Subjects: A Randomized, Double-Blind, Placebo-, and Active-Controlled Thorough QT Study

(2012) M Malik et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder

(2012) Christopher R. Chapple et al.   EUROPEAN UROLOGY

Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial

(2012) Vik Khullar et al.   EUROPEAN UROLOGY

Results of a Randomized Phase III Trial of Mirabegron in Patients with Overactive Bladder

(2012) Victor W. Nitti et al.   JOURNAL OF UROLOGY

Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence

(2009) Karl-Erik Andersson et al.   CURRENT OPINION IN UROLOGY

Reviewing the ICS 2002 terminology report: The ongoing debate

(2009) Paul Abrams et al.   NEUROUROLOGY AND URODYNAMICS

Stimulation of β3-adrenoceptors relaxes rat urinary bladder smooth muscle via activation of the large-conductance Ca2+-activated K+ channels

(2008) Kiril L. Hristov et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Potentiation of Potassium Currents by Beta-Adrenoceptor Agonists in Human Urinary Bladder Smooth Muscle Cells: A Possible Electrical Mechanism of Relaxation

(2008) Jun Takemoto et al.   PHARMACOLOGY